MV Capital Management’s Loncar China BioPharma ETF CHNA Stock Holding History

MV Capital Management’s Portfolio CHNA Stock Details CHNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-400	Closed	-$19K	–	731
2021 Q2	$19K	Buy	+400	New	+$16.9K	﹤0.01%	291

Other funds holding CHNA

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

FEM

Fulcrum Equity Management Plano, Texas $136M AUM 42.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

MV Capital Management's CHNA Position: Q3 2021 in Review

MV Capital Management sold out of Loncar China BioPharma ETF (CHNA) in Q3 2021, closing a stake of 400 shares — an estimated $19K sold.

MV Capital Management first reported a position in CHNA in Q2 2021 and held it in 1 quarter. The position peaked at $19K in Q2 2021. 6 funds tracked by Wall St. Rank hold CHNA as of Q3 2021.

MV Capital Management reported no remaining Loncar China BioPharma ETF position as of Q3 2021 after selling out during the quarter.
MV Capital Management sold 400 Loncar China BioPharma ETF shares in Q3 2021, an estimated $19K.
MV Capital Management first reported a position in Loncar China BioPharma ETF in Q2 2021 and held it in 1 quarter.
MV Capital Management's Loncar China BioPharma ETF position peaked at $19K in Q2 2021.
6 funds tracked by Wall St. Rank held Loncar China BioPharma ETF as of Q3 2021.

Based on MV Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.